MSI2 protective variant against blood cancer discovered

Overview

For decades, cancer genetics meant finding mutations that raise risk. Now scientists have found one that lowers it. A variant in the MSI2 gene reduces the risk of blood cancers by up to 30% in people who carry two copies—the first protective genetic variant identified against myeloid malignancies.

The discovery, published January 1, 2026 in Science by researchers from Memorial Sloan Kettering, Harvard, and Vanderbilt, shows a new strategy for cancer prevention. Rather than just identifying who's at risk, the finding points toward interventions that could prevent blood cancer by mimicking what this natural variant does: dial down a protein that precancerous cells need to outcompete healthy ones.

Play on this story Voices Debate Who Said What? Predict

Key Indicators

30%

Risk reduction (two copies)

People with the variant in both gene copies show 30% decreased risk of clonal hematopoiesis

20%

Myeloid disease protection

Single-copy carriers have 20% lower risk of developing myeloid malignancies including leukemia

Global variant prevalence

Approximately 4% of humans carry this protective variant, with highest rates in Finnish populations

1.8x

Clone regression likelihood

Variant carriers are 1.8 times more likely to see precancerous blood cell clones disappear entirely

Voices

Curated perspectives — historical figures and your fellow readers.

Ever wondered what historical figures would say about today's headlines?

Play

Exploring all sides of a story is often best achieved with Play.

Predict 4 ways this could play out. Contrarian picks score more — points lock when the scenario resolves. Log in to play

Timeline Five events from this story — drag them oldest to newest. Log in to play

Connections Sixteen names from the news. Find the four hidden groups of four. Log in to play

People Involved

Michael Kharas

Co-corresponding author of the Science paper

Vijay Sankaran

Senior author of the Science paper

Alexander Bick

Co-author leading validation studies

Yash Pershad

Led longitudinal validation analysis

Koichi Takahashi

Expert commentator on therapeutic implications

Organizations Involved

Memorial Sloan Kettering Cancer Center

Cancer Research Hospital

Co-led the research

One of the world's premier cancer centers, where the Kharas lab has studied MSI2 for over a decade.

Harvard Stem Cell Institute

Academic Research Institute

Co-led the research

Harvard's hub for stem cell science, where Sankaran's lab studies genetic variation in blood cell production.

Vanderbilt BioVU

DNA Biobank

Provided longitudinal validation data

The world's largest DNA biobank linked to electronic health records at a single academic center.

JAMA Oncology

Medical Journal

Peer-reviewed oncology journal that published complementary research on clonal hematopoiesis and cardiovascular disease risk.

Timeline

1994 January 2026

11 events Latest: January 24th, 2026 · 4 months ago Showing 8 of 11

Tap a bar to jump to that date

January 2026
Research Gains Widespread Attention
Latest Coverage

Multiple outlets report on the MSI2 discovery, highlighting implications for blood cancer prevention and potential therapeutic development.
January 24th, 2026
CHIP Linked to Heart Disease Risk After Cancer Treatment
Research

Bick lab published in JAMA Oncology showing that 1 in 5 cancer patients with clonal hematopoiesis face increased cardiovascular disease risk following cancer therapy, supporting the need for CHIP screening before treatment.
January 8th, 2026
Protective MSI2 Variant Discovery Published
Publication

Science published the multi-institutional study identifying rs17834140-T variant that reduces blood cancer risk by up to 30%, with mechanism explained.
January 1st, 2026
December 2023
FDA Approves First Gene Therapy for Sickle Cell
Regulatory

Casgevy approved by FDA, based partly on Sankaran's research on BCL11A—demonstrating his lab's track record translating genetic discoveries to therapies.
December 2023
April 2023
TCL1A Identified as Blood Cancer Prevention Target
Research

Bick lab published in Nature identifying TCL1A as a gene driving clonal expansion, suggesting drugs targeting it could suppress cancerous growth.
April 12th, 2023
June 2019
First MSI2 Inhibitor Molecule Identified
Drug Development

Kharas lab reported in Nature Communications that compound 'Ro' blocks Musashi-2 function, eliminating tumor cells and normalizing leukemic cells in mice.
June 19th, 2019
2017
MSI2 Role in Myeloid Leukemia Confirmed
Research

Nature Genetics published functional screen identifying MSI2's essential role in myeloid leukemia stem cells through its interaction with SYNCRIP.
2017
2015
Kharas Lab Links MSI2 to Leukemia Stem Cells
Research

Published in Journal of Clinical Investigation, demonstrating that Musashi2 sustains the stem cell program in MLL-driven leukemia.
2015
November 2014
Landmark NEJM Studies on Clonal Hematopoiesis
Publication

New England Journal of Medicine published studies showing clonal hematopoiesis is a strong risk factor for blood cancer (12.9x hazard ratio) and associated with increased mortality.
November 26th, 2014
2012
TET2 Mutations Linked to Clonal Hematopoiesis
Research

Nature Genetics published research identifying recurrent somatic TET2 mutations in elderly individuals with clonal hematopoiesis, establishing the genetic basis of CHIP.
2012
1994
Musashi Gene Discovered in Fruit Flies
Discovery

Neurobiologist Craig Montell identified the Musashi gene controlling cell division in Drosophila. Named for the Japanese samurai's two swords, referencing the double-bristle mutation phenotype.
1994

#timeline [x-show="expanded"] { display: revert !important; opacity: 1 !important; } #timeline .timeline-toggle-btn { display: none; }

Historical Context

3 moments from history that rhyme with this story — and how they unfolded.

1996-2024

CCR5-Δ32 and HIV Resistance (1996)

Scientists discovered that a 32-base-pair deletion in the CCR5 gene renders homozygous carriers nearly immune to HIV infection. About 1% of Northern Europeans carry two copies. The discovery emerged from studying why some highly-exposed individuals never contracted HIV.

Then

Identified CCR5 as HIV entry co-receptor, explaining the protective mechanism. Began hunt for drugs mimicking the deletion's effect.

Now

CCR5-targeted drugs (maraviroc) approved. At least five HIV patients 'cured' via stem cell transplants from CCR5-Δ32 donors. Gene therapy trials underway to edit CCR5 in patients' cells.

Why this matters now

The MSI2 discovery follows the same paradigm: natural protective variants pointing toward therapeutic targets. Like CCR5, MSI2 shows that studying why some people don't get sick can be as valuable as studying why others do.

December 2023

BCL11A and Fetal Hemoglobin Reactivation (2008-2023)

Vijay Sankaran, co-author on the MSI2 paper, identified BCL11A as the switch suppressing fetal hemoglobin production in adults. People with naturally lower BCL11A activity had milder sickle cell disease. His lab developed gene therapy approaches to reduce BCL11A.

Then

Proved that mimicking natural protective genetic variation could treat blood disorders.

Now

Casgevy, the first FDA-approved CRISPR gene therapy, uses BCL11A editing to treat sickle cell disease and beta-thalassemia. Over 45 patients treated in trials showed durable responses.

Why this matters now

Same research team, same approach: find people protected by natural variation, understand the mechanism, develop therapy that mimics it. MSI2 is their next target.

1998-Present

Tamoxifen and BRCA Carriers (1998-Present)

While BRCA mutations dramatically increase breast cancer risk, researchers found that tamoxifen reduces contralateral breast cancer risk by 50-69% in BRCA carriers. This demonstrated that high-risk genetic status doesn't preclude effective prevention.

Then

Established cancer prevention as viable strategy even in genetically high-risk populations.

Now

Chemoprevention became standard discussion for BRCA carriers. Showed that genetic risk assessment plus intervention beats genetic risk assessment alone.

Why this matters now

MSI2 research inverts this: instead of finding drugs for high-risk variants, it finds therapeutic targets from protective variants. But the goal is the same—using genetics to prevent cancer before it starts.